Hikma Pharmaceuticals Plc Hikma Appoints Dr. Surendera Tyagi
January 15 2018 - 3:00AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
15 January 2018
PRESS RELEASE
Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific
Officer and Global Head of R&D
London, 15 January 2018 - Hikma Pharmaceuticals PLC (Hikma,
Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1
Moody's / BB+ S&P, both stable), today announced that Surendera
Tyagi, PhD, will join Hikma as Group Chief Scientific Officer and
Global Head of Research and Development. Dr Tyagi will focus on the
Group's non-injectables business during the first year and will
become a member of Hikma's Executive Committee.
"Surendera is an outstanding scientist with a proven track
record of leading research and development in some of the world's
largest and most successful pharmaceutical organizations," said
Saïd Darwazah, Chairman and Chief Executive Officer, Hikma.
"Research and Innovation is one of our five pillars for growth and
the appointment of Surendera is a significant step forward in
executing on this strategy. We are very excited for Surendera to be
joining us and accelerating our ability to develop novel ways to
improve the health of people around the world."
Dr Tyagi joins from Fresenius Kabi, where he most recently led
their US Innovation & Development Center. While at Fresenius,
he successfully expanded the company's oncology business. Prior to
joining Fresenius Kabi, Dr Tyagi served as Chief Scientific Officer
for Dabur Pharma, an oncology company that was acquired by
Fresenius in 2008. He also has held scientific and/or regulatory
roles at Roche, IGEN, Abbott/Hospira, and Schwarz Pharma with
increasing management responsibilities.
Dr Tyagi has been an active member of the Association for
Affordable Medicines, and participated in GDUFA II negotiations
with the FDA.
"I am delighted to be joining Hikma at this exciting time in the
company's journey, leading such an important function," said Dr
Tyagi. "Hikma's track record of delivering affordable, quality
medicines to people who need them is a purpose that I share. I look
forward to accelerating their R&D efforts by advancing and
expanding their pipeline, leveraging Hikma's highly experienced and
talented R&D team."
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Brooke Clarke, VP Corporate
Affairs +44 (0)20 7399 2760
FTI Consulting
Ben Atwell/ Brett Pollard +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical
group focused on developing, manufacturing and marketing a broad
range of both branded and non-branded generic and in-licensed
products. Hikma's operations are conducted through three
businesses: 'Injectables,' 'Generics' and 'Branded,' based
primarily in the Middle East and North Africa (MENA) region, where
it is a market leader, the United States and Europe. In 2016, Hikma
achieved revenues of $1,950 million and profit attributable to
shareholders of $155 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFVLLFISLIT
(END) Dow Jones Newswires
January 15, 2018 03:00 ET (08:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024